Telix signs agreement with Radius for distribution of Illuccix in Italy
Author : Pankaj Singh | Published Date : 2021-09-13
- Radius will be the exclusive distributor for Illuccix in Italy for three years following the national approval date.
- Radius and Telix Pharma had previously joined hands for the distribution of Ga-PSMA-11 for magisterial use in Italy.
Telix Pharmaceuticals Limited has reportedly entered into an agreement with Radius S.r.l for the exclusive commercial distribution of Illuccix, Telix’s prostate cancer imaging product, in Italy.
Under the terms of the contract, Radius will be the exclusive distributor for Illuccix in Italy for three years following the national approval date. The radiotherapy solutions provider had previously partnered with Telix Pharmaceuticals for the distribution of Ga-PSMA-11 for magisterial use in Italy.
It is also worth noting that Radius is the industry leader in the supply of gallium generators across Italy which enables it to provide a secure supply of the gallium required for launching Illuccix. The company is also a service provider and supplier for radiotherapy suites and cyclotrons across Italy which lends it a competitive edge.
Chief Executive Officer of Radius Dr. Mauro Mei was quoted saying that the partnership with Telix Pharmaceuticals will enable the company to provide state-of-the-art PSMA imaging facilities to the 39,000 men diagnosed with prostate cancer in Italy every year following the required regulatory approval.
EMEA President at Telix Pharmaceuticals Richard Valeix mentioned that Italy is an important market considering the high incidence of prostate cancer in the country. He further added that the partnership with Radius, which is already a renowned patient-centric company specializing in nuclear medicine, will enable Telix to achieve its mission of helping cancer patients live longer and better lives.
In 2020, prostate cancer was the most diagnosed type of cancer among Italian men with approximately 39,000 new cases being recorded. It was also a leading cause of cancer-related deaths among men in Italy with 7000 deaths registered during the year.
Source Credits--
About Author
Pankaj Singh . .
Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605
Related News
BlackRock invests $700 million in Australian battery storage company
BlackRock Real Assets, one of the world’s major asset management firms, is reportedly planning to acquire Akyasha Energy, an Australia-based firm specializing in battery storage & renewable energy projects. BlackRock has recently stated that it aims to commit an additional capital of $7... Read More>>
Reebok owner Authentic Brands to acquire British firm Ted Baker for $254Mn
The retail company Authentic Brands Group, which owns brands like Juicy Couture, Reebok, and Forever 21, has reportedly struck a $254 million deal to acquire the U.K. clothing retailer Ted Baker. With 110 pence paid in cash in return for each Ted Baker share, the purchase... Read More>>
Organto allies with Netherlands-based retailer to launch organic products
Organto Foods Inc., an innovative, fast-growing global provider of fresh organic fruits & vegetables, has recently announced the introduction of its “I AM Organic” products in the Netherlands, in collaboration with an industry-leading petrol and charge station provider. Initial la... Read More>>